NervGen Pharma Corp. Form 6-K Summary
Business Context and Reporting Period
NervGen Pharma Corp., a Canadian foreign private issuer, furnished this Form 6-K for the month of September 2026. The report was signed and submitted on September 24, 2026, by Keith Vendola, Chief Financial Officer.
Financial Metrics
The filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes
The filing includes a Notice of Change of Auditor dated September 15, 2026, together with response letters from KPMG LLP (Canada) and KPMG LLP (U.S.). The supplied filing text does not clearly state the identity of the successor auditor, the effective date of the change, or the reasons for the change.
Guidance, Risks, and Unusual Items
No financial guidance, operating outlook, management commentary, contingencies, or specific risk factors are provided in the filing text. The auditor change is the principal disclosed corporate event.
Exhibits 99.1 and 99.2 are incorporated by reference into the company’s Form F-10 and specified Form S-8 registration statements, subject to subsequent filings. Exhibit 99.3 is the U.S. KPMG response letter.
Investor Verification Items
- Review Exhibit 99.1 for the successor auditor, effective date, and stated reasons for the auditor change.
- Review Exhibits 99.2 and 99.3 for any disagreements, reportable events, scope limitations, or other matters raised by KPMG.
- Confirm whether subsequent filings provide additional explanation or financial implications related to the auditor transition.